MAZE compared with ERAS: revenue, margins and what each company keeps, and the suppliers and customers both name

MAZEMaze Therapeutics, Inc.

Mkt capRevenueRevenue

ERASErasca, Inc.

Mkt capRevenueRevenue

Compare

MAZEMaze Therapeutics, Inc.

ERASErasca, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

MAZEMaze Therapeutics, Inc.

31.42▼−1.60%· post 31.10

Mkt cap$1.9BRevenue$20MQ1 FY26

ERASErasca, Inc.

14.33▼−4.34%· post 14.20

ClosedOct 30 '26

Mkt cap$5.0BRevenue—

Compare

ClosedOct 30 '26

MAZEMaze Therapeutics, Inc.

ERASErasca, Inc.

31.42▼−1.60%post 31.10

Price

14.33▼−4.34%post 14.20

$1.9B

Mkt cap

$5.0B

Q1 FY26$20M

Revenue

—

MAZE31.42▼−1.60%vsERAS14.33▼−4.34%ClosedOct 30 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

rebased to 0%

MAZE, solidERAS, dashed

Supply-chain overlap

Revenue flow

MAZE: latest quarter is a loss; flow not drawable. ERAS: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only MAZE 4

NBIXNeurocrine Biosciencescustomer

—Shionogiunlistedcustomer

—Trace Neuroscienceunlistedcustomer

—Alloy Therapeuticsunlistedcustomer

Shared 0

No shared counterparties.

Only ERAS 5

—Emerge Life Sciences, Pteunlistedsupplier

—Guangzhou Joyo Pharmatechunlistedsupplier

—Medshine Discoveryunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—Novartis Pharmaunlistedsupplier

1 more · ERAS chain ›